Outset Medical heads into its third-quarter report with a story that improved on paper last quarter while the stock went the other way. The dialysis-technology company delivered its strongest console quarter in recent memory, landed its first refresh contract, a $40 million agreement with HCA Healthcare, and sounded noticeably more confident than it did a year ago, when it cut guidance and lost its head of sales. Yet shares have fallen 15% since that report, trailing a roughly flat S&P 500 by more than 14 points. The November 4 release, due after the close, is the market's chance to decide whether last quarter marked an inflection or a one-off.

The Street expects a loss of $0.84 per share on revenue of about $31.5 million. That would be a narrower loss than the $0.98 posted a year ago and a 7% revenue gain from $29.4 million, but essentially flat with the $31.6 million reported in the second quarter. Management has reaffirmed its 2026 revenue outlook of $125 million to $130 million for four straight calls, and full-year consensus of $127.5 million sits right at the midpoint. Because the company has repeatedly described growth as back-half weighted, a third quarter that merely matches the second leaves more of the burden on the fourth. A soft print here would quickly raise the question of whether the low end of the range is still safe.

The most important line item is consumables, the recurring revenue that should reflect how heavily installed Tablo machines are actually used. Consumable sales have slid for three quarters, reaching $12.4 million in the second quarter, down 12% from a year earlier and a steeper drop than the prior quarter. Management blamed tough comparisons and past ordering patterns rather than weaker utilization. This quarter tests that explanation directly: the year-ago consumable figure was $12.2 million, a much easier hurdle. If consumables cannot return to growth against that comparison, the timing argument loses credibility, and the overall recurring-revenue decline of 2% becomes harder to dismiss.

Consoles present the opposite challenge. Second-quarter console revenue of $9.5 million crushed expectations, partly because of pull-through from the HCA deal. The year-ago quarter brought $8.3 million in console sales, so holding that level would show the rebound has legs beyond a single customer. Management also left HCA's phasing through 2028 undisclosed, so any added color on timing, or progress toward the broader opportunity of roughly 3,000 consoles and up to $150 million in refresh revenue, would help turn a headline contract into a forecastable pipeline. The next-generation Tablo launch is another checkpoint; it slipped from a late second-quarter target into a pilot phase, and further delay would undercut the refresh narrative.

Margins and cash round out the scorecard. Gross margin has climbed from 39.9% to 42.2% over the past year, though the console-heavy mix pressured product margins last quarter. Holding in the low 40s while service margins stay elevated would keep the 50% goal plausible, and reiterating full-year cash use below $40 million matters for a company still losing money.

Sentiment has swung from modestly bearish before the last report to modestly bullish now, even as the stock has slipped just below its 200-day moving average near $4.17, trading in the upper half of a $2.84 to $5.28 post-earnings range. That combination suggests investors want to believe but need proof. The verdict likely hinges on whether consumables stabilize while consoles hold up; both together would validate the turnaround, while another consumable decline would make last quarter's optimism look premature.